Moxifloxacin in Pediatric Subjects With Complicated Intra-abdominal Infection (MOXIPEDIA)

• ClinicalTrials.gov Identifier: NCT01069900
• Recruitment Status: Completed
• First Posted: February 17, 2010
• Results First Posted: December 8, 2015
• Last Update Posted: March 20, 2018
• Sponsor: Bayer
• Information provided by (Responsible Party): Bayer

Study Description

Brief Summary:

The primary focus of the study is the evaluation of the safety of treatment with moxifloxacin in a pediatric population 3 months to <18 years old. Approximately 450 pediatric subjects with a complicated intra-abdominal infection will be enrolled in the study and treated with either moxifloxacin intravenously and orally if switched to oral therapy or ertapenem (intravenously) and, if switched to oral therapy, amoxicillin/clavulanate.

Condition or disease	Intervention/treatment	Phase
Intraabdominal Infections	Drug: Moxifloxacin (Avelox, BAY12-8039); Drug: Ertapenem; Drug: Amoxicillin/Clavulanate; Drug: Moxifloxacin placebo; Drug: Ertapenem placebo; Drug: Amoxicillin/Clavulanate placebo	Phase 3

Study Design

• Study Type: Interventional (Clinical Trial)
• Actual Enrollment: 458 participants
• Allocation: Randomized
• Intervention Model: Parallel Assignment
• Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
• Primary Purpose: Treatment
• Official Title: A Randomized, Double-blind, Multicenter Trial to Evaluate the Safety and Efficacy of Sequential (Intravenous, Oral) Moxifloxacin Versus Comparator in Pediatric Subjects With Complicated Intra-abdominal Infection
• Actual Study Start Date: July 21, 2010
• Actual Primary Completion Date: January 21, 2015
• Actual Study Completion Date: January 21, 2015

Arms and Interventions

Arm	Intervention/treatment
Experimental: Moxifloxacin (Avelox, BAY12-8039); Subjects randomized to the moxifloxacin arm of this study received intravenous moxifloxacin plus ertapenem placebo (0.9 % sodium chloride [NaCl solution]) for a minimum of 3 days and, if switched to oral treatment, PO moxifloxacin plus PO amoxicillin/clavulanate placebo. Total treatment duration is 5-14 days.	Drug: Moxifloxacin (Avelox, BAY12-8039); For subjects 12 to less than (<) 18 years of age and weighing at least 45 kilograms (kg), the dose of moxifloxacin will be 400 milligrams (mg), once daily (OD). Subjects 12 to < 18 years of age and weighing less than 45 kg, the dose of moxifloxacin will be 4 mg/kg twice daily (BID), every 12 hours (q12h), not exceeding 400 mg/day. Subjects 6 to < 12 years of age the dose of moxifloxacin will be 4mg/kg, q12h, not exceeding 400 mg/day. Subjects 2 to less than 6 years of age the dose of moxifloxacin will be 5mg/kg, q12h, not exceeding 400 mg/day. Subjects 3 months to less than 2 years of age the dose of moxifloxacin will be 6mg/kg q12h IV, not exceeding 400 mg/day. Subjects who were switched from IV to PO therapy, 400 mg or 50 mg moxifloxacin tablets were provided.; Drug: Ertapenem placebo; Sterile 0.9% sodium chloride solution intended for IV use was used as the placebo for IV ertapenem.; Drug: Amoxicillin/Clavulanate placebo; Suspension containing inactive ingredients was used as the placebo for PO amoxicillin/clavulanate suspension.
Active Comparator: Comparator Ertapenem; Subjects randomized to the comparator arm of this study received intravenous ertapenem plus moxifloxacin placebo (0.9 % NaCl solution) for a minimum of 3 days and, if switched to oral treatment, amoxicillin/clavulanate as an oral suspension plus PO moxifloxacin placebo. Total treatment duration is 5-14 days.	Drug: Ertapenem; For subjects 13 to <18 years of age, the dosage of ertapenem was 1 gram (g) OD. For subjects 3 months to < 13 years of age, the dosage was 15 mg/kg q12h not to exceed 1 g/day.; Drug: Amoxicillin/Clavulanate; Subjects 2 years to < 18 years of age who were switched from IV to PO therapy receive amoxicillin/clavulanate suspension. The dosage of clavulanate was 3.2 mg/kg q12h. (maximum dose of clavulanate was 125 mg q12h). The dosage of amoxicillin was 22.5 mg q12h (a maximum dose of 875 mg amoxicillin q12h must not be exceeded).; Drug: Moxifloxacin placebo; Sterile 0.9% sodium chloride solution intended for IV use was used as the placebo for IV moxifloxacin. Tablets containing inactive ingredients were used as the placebo for PO moxifloxacin 400 mg and 50 mg tablets.

Outcome Measures

Primary Outcome Measures :

1. Number of Subjects With Adverse Events [ Time Frame: All AEs and SAE were recorded from treatment start to test of cure visit; musculoskeletal AEs were recorded up to 1 year post-end of treatment (EOT) visit; subjects with musculoskeletal AEs 1 year after EOT were followed up to 5 years or until resolution. ]
   An adverse event (AE) was any untoward medical occurrence in a subject who received study drug without regard to possibility of causal relationship. An serious adverse event (SAE) was an AE resulting in any of the following outcomes or deemed significant for any other reason: death; initial or prolonged inpatient hospitalization; life-threatening experience (immediate risk of dying); persistent or significant disability/incapacity; congenital anomaly.
2. Number of Subjects With Clinical Cardiac Adverse Events [ Time Frame: Clinical cardiac event related to QT interval were recorded from treatment start until day 3 of treatment. All other clinical cardiac events were recorded from treatment start to test of cure visit, up to day 56. ]
3. Number of Subjects With Musculoskeletal Adverse Events [ Time Frame: All AEs and SAE were recorded from treatment start to test of cure visit; musculoskeletal AEs were recorded up to 1 year post-end of treatment (EOT) visit; subjects with musculoskeletal AEs 1 year after EOT were followed up to 5 years or until resolution. ]

Secondary Outcome Measures :

1. Incidence Rates of Musculoskeletal Adverse Events by Primary System Organ Class (SOC) and Preferred Term [ Time Frame: All AEs and SAE were recorded from treatment start to test of cure visit; musculoskeletal AEs were recorded up to 1 year post-end of treatment (EOT) visit; subjects with musculoskeletal AEs 1 year after EOT were followed up to 5 years or until resolution. ]
   Musculoskeletal adverse events were classified as following SOCs (preferred terms): "injury, poisoning and procedural complications" (forearm fracture, joint injury, ligament sprain, muscle strain) "musculoskeletal and connective tissue disorders" (arthralgia, joint swelling, musculoskeletal pain, myalgia). Incidence rates were reported as percentage of subjects categorized under preferred terms.
2. Heart Rate Changes in Electrocardiogram (ECG) Profiles From Pre-dose to Post-dose on Treatment Day 1 and Treatment Day 3 [ Time Frame: Baseline (Pre-dose), Day 1, Day 3 ]
   "N" signifies subjects who were evaluable for the specified parameter for each arm, respectively.
3. PR Interval Changes in Electrocardiogram (ECG) Profiles From Pre-dose to Post-dose on Treatment Day 1 and Treatment Day 3 [ Time Frame: Baseline (Pre-dose), Day 1, Day 3 ]
   The PR interval is defined as the period that extends from the onset of atrial depolarization (beginning of the P wave) until the onset of ventricular depolarization. "N" signifies subjects who were evaluable for the specified parameter for each arm, respectively.
4. RR Interval Changes in Electrocardiogram (ECG) Profiles From Pre-dose to Post-dose on Treatment Day 1 and Treatment Day 3 [ Time Frame: Baseline (Pre-dose), Day 1, Day 3 ]
   The RR interval refers to the respective time interval in the Electrocardiogram. "N" signifies subjects who were evaluable for the specified parameter for each arm, respectively.
5. QRS Interval Changes in Electrocardiogram (ECG) Profiles From Predose to Post-dose on Treatment Day 1 and Treatment Day 3 [ Time Frame: Baseline (Pre-dose), Day 1, Day 3 ]
   The QRS interval represents the time it takes for ventricular depolarization to occur. "N" signifies subjects who were evaluable for the specified parameter for each arm, respectively.
6. QT Interval Changes in Electrocardiogram (ECG) Profiles From Pre-dose to Post-dose on Treatment Day 1 and Treatment Day 3 [ Time Frame: Baseline (Pre-dose), Day 1, Day 3 ]
   The QT interval is the period that extends from the beginning of ventricular depolarization until the end of ventricular repolarization. "N" signifies subjects who were evaluable for the specified parameter for each arm, respectively.
7. Corrected QT (QTc) Interval Calculated (Calc) Bazett Changes in Electrocardiogram (ECG) Profiles From Pre-dose to Post-dose on Treatment Day 1 and Treatment Day 3 [ Time Frame: Baseline (Pre-dose), Day 1, Day 3 ]
   QTc interval Calc Bazett represent the interval corrected for heart rate (QTc) milliseconds (msec) which was calculated by Bazett's method. "N" signifies subjects who were evaluable for the specified parameter for each arm, respectively.
8. Corrected QT (QTc) Interval Calculated (Calc) Fridericia Changes in Electrocardiogram (ECG) Profiles From Pre-dose to Post-dose on Treatment Day 1 and Treatment Day 3 [ Time Frame: Baseline (Pre-dose), Day 1, Day 3 ]
   QTc interval Calc Fridericia represent the interval corrected for heart rate (QTc) msec which was calculated by Fridericia's method. "N" signifies subjects who were evaluable for the specified parameter for each arm, respectively.
9. Potentially Clinically Significant Electrocardiogram (ECG) QTc Interval Prolongation - by QTc Interval Calc Fridericia Correction on Treatment Day 1 and During Therapy Day 3 [ Time Frame: Baseline (Pre-dose), Day 1, Day 3 ]
   A significant QTc prolongation was considered when the QTc value was more than (>) upper limit of normal (ULN) range or was prolonged for 30 msec or 60msec in comparison with the pre-treatment value measured on Day 1. "N" signifies subjects who were evaluable for the specified parameter for each arm, respectively. Percentage of subjects with potentially clinically significant ECG data was reported.
10. Potentially Clinically Significant Electrocardiogram (ECG) QTc Interval Prolongation - by QTc Calc Bazett Correction on Treatment Day 1 and During Therapy Day 3 [ Time Frame: Baseline (Pre-dose), Day 1, Day 3 ]
    A significant QTc prolongation was considered when the QTc value was more than ULN range or was prolonged for 30 msec or 60msec in comparison with the pre-treatment value measured on Day 1. "N" signifies subjects who were evaluable for the specified parameter for each arm, respectively. Percentage of subjects with potentially clinically significant ECG data was reported.
11. Clinical Response at Test-of-Cure (TOC) Visit [ Time Frame: 28 to 42 days ]
    Clinical responses were graded as clinical cure, failure or indeterminate. 'Clinical cure' defined as a resolution or sufficient improvement of clinical signs and symptoms related to the infection; 'failure' defined as a reappearance of the signs and symptoms of the original infection, or wound infection requiring further systemic antimicrobial therapy; 'indeterminate' defined as those subjects in whom a clinical assessment was not possible to determine (due to early withdrawal from the study because of adverse events, protocol violation, withdrawn consent). Percentage of subjects with clinical response at TOC were reported.
12. Bacteriological Response at Test-of-Cure (TOC) Visit [ Time Frame: 28 to 42 days ]

    Bacteriological responses were graded as presumed persistence, presumed eradication or indeterminate.

    'Presumed persistence' was applicable for subjects judged to be clinical failures, and appropriate culture material is not available for evaluation; 'presumed eradication' defined as the absence of appropriate culture material for evaluation because the subject has clinically responded and invasive procedures are not warranted; índeterminate' was applicable when the bacteriological response to the study drug was not valid for any reason (eg, pre-treatment culture was negative or culture was not obtained when material was available and the subject was not judged a clinical failure). Percentage of subjects with bacteriological response at TOC were reported.

13. Clinical Response at Test-of-Cure (TOC) Visit in Subjects With Bacteriologically Confirmed Complicated Intra-abdominal Infection (cIAI) [ Time Frame: 28 to 42 days ]
    Clinical responses were graded as clinical cure, failure or indeterminate. 'Clinical cure' defined as a resolution or sufficient improvement of clinical signs and symptoms related to the infection; 'failure' defined as a reappearance of the signs and symptoms of the original infection, or wound infection requiring further systemic antimicrobial therapy; 'indeterminate' defined as those subjects in whom a clinical assessment was not possible to determine (due to early withdrawal from the study because of adverse events, protocol violation, withdrawn consent). Percentage of subjects with clinical response at TOC were reported
14. Clinical Response at a 'During Therapy' Visit [ Time Frame: Day 3 to Day 5 ]

    Clinical responses during therapy visit were graded as clinical improvement, clinical failure, or indeterminate. Clinical improvement defined as a reduction in the severity and/or the number of signs and symptoms of infection; 'clinical failure' defined as a failure to respond or insufficient lessening of the signs and symptoms of infection requiring a modification or addition of antibacterial therapy.

    'Indeterminate' defined as those subjects in whom a clinical assessment is not possible to determine (eg, due to early withdrawal from the study because of adverse events, protocol violation, withdrawn consent, receipt of an effective concomitant antibacterial for an indication other than the study indication and receipt of less than 3 full days of study drug, etc). Percentage of subjects with clinical response during therapy visit were reported.

15. Bacteriological Response at a 'During Therapy' Visit [ Time Frame: Day 3 to Day 5 ]
    Bacteriological response during therapy were graded as presumed persistence, presumed eradication, or indeterminate'Presumed persistence' is applicable for subjects judged to be clinical failures and appropriate culture material is not available for evaluation;'presumed eradication' is defined as the absence of appropriate culture material for evaluation because the subject has clinically responded (with a response as a resolution or cure) and invasive procedures are not warranted; 'indeterminate is applicable when the bacteriological response to the study drug is not valid for any reason (eg, pretreatment culture was negative or culture was not obtained when material was available and the subject is not judged a clinical failure). Percentage of subjects with bacteriological response during therapy visit were reported
16. Clinical Response at the End-of-Treatment (EOT) Visit [ Time Frame: Day 5 to Day 14 ]
    Clinical responses at EOT were graded as resolution, failure, or indeterminate. 'Resolution' defined as a disappearance of signs and symptoms related to the infection or sufficient improvement of clinical signs and symptoms related to the infection and the subject does not require any further antibiotic therapy or surgical intervention; 'failure' defined as worsening or insufficient lessening of the signs and symptoms of infection requiring a modification or addition of antibacterial therapy; 'indeterminate' is defined as those subjects in whom a clinical assessment is not possible to determine (eg, due to early withdrawal from the study because of adverse events, protocol violation, withdrawn consent; receipt of less than 3 full days of study drug; receipt of an effective concomitant antibacterial for an indication other than study indication; etc). Percentage of subjects with clinical response at EOT were reported.
17. Bacteriological Response at the End of Treatment (EOT) Visit [ Time Frame: Day 5 to Day 14 ]
    Bacteriological response at EOT were grades as presumed persistence, presumed eradication or indeterminate. 'presumed persistence' was applicable for subjects judged to be clinical failures and appropriate culture material is not available for evaluation; 'presumed eradication' defined as the absence of appropriate culture material for evaluation because the subject has clinically responded (with a response as a resolution or cure) and invasive procedures are not warranted; 'indeterminate' is applicable when the bacteriological response to the study drug was not valid for any reason (eg, pretreatment culture was negative or culture was not obtained when material was available and the subject was not judged a clinical failure). Percentage of subjects with bacteriological response at EOT were reported.

Eligibility Criteria

• Ages Eligible for Study: 3 Months to 17 Years (Child)
• Sexes Eligible for Study: All
• Accepts Healthy Volunteers: No

Criteria

Inclusion Criteria:

• Hospitalized males or females 3 months to 17 years of age
• Able to obtain parental or legal guardian written informed consent and assent from subjects as applicable by local laws and regulations
• Expected duration of treatment with antibiotics is a minimum of 3 days administered IV, for a total of 5 to 14 days administered IV or IV followed by PO
• If the subject is a female of child-bearing potential she must have a negative pregnancy test at the screening visit or be capable of practicing an adequate method of contraception, and agree to continue the same method for 1 month following the TOC visit. Lactating subjects are not to be included.

• Subjects may be enrolled upon a surgically (laparotomy, laparoscopy, or percutaneous drainage) confirmed cIAI revealing at least one of the following:

  • Gross peritoneal inflammation with purulent exudate within the abdominal cavity
  • Intra-abdominal abscess
  • Macroscopic intestinal perforation with diffuse peritonitis OR

• Subjects may be enrolled on the basis of a suspected cIAI, which must be supported with radiological evidence (ultrasound, abdominal plain films, computed tomography [CT], magnetic resonance imaging [MRI]) of gastrointestinal perforation or localized collections of potentially infected material and at least one of the following:

  • Symptoms referable to the abdominal cavity (eg, anorexia, nausea, vomiting or pain)
  • Tenderness (with or without rebound), involuntary guarding, absent or diminished bowel sounds, or abdominal wall rigidity
  • Fever
  • Leukocytosis
• The subject must be scheduled for a surgical procedure (laparotomy or laparoscopy) or percutaneous drainage.

Exclusion Criteria:

• Presumed spontaneous bacterial peritonitis
• All pancreatic processes including pancreatic sepsis, peripancreatic sepsis, or an cIAI secondary to pancreatitis
• Early acute or suppurative (nonperforated) appendicitis unless there is evidence of an abscess or peritoneal fluid containing pus and micro-organisms suggestive of regional contamination
• Infections originating from the female genital tract
• Known severe immunosuppression. Subjects with known mild immunosuppression (eg, Type I or II diabetes mellitus, trauma, or absolute neutrophil count [ANC] between 1000 and 1500 cells/mm3) may be enrolled.
• Congenital or documented acquired QT prolongation
• Receiving concomitant treatment with QT prolonging drugs
• History of tendon disease/disorder related to quinolone treatment
• Pathogenic organisms suspected or identified (eg, Pseudomonas) which are resistant to any of the study drugs
• Abnormal musculoskeletal findings at baseline assessment; or chronic musculoskeletal disease (eg, juvenile rheumatoid arthritis); or chronic illness with high risk for chronic or recurrent arthritis or tendinitis (eg, cystic fibrosis, chronic inflammatory bowel disease)
• History of myasthenia gravis

Contacts and Locations

Locations

United States, California

San Diego, California, United States, 92123

United States, Massachusetts

Springfield, Massachusetts, United States, 01199

Argentina

Hospital de Agudos "Dr. Carlos Bocalandro"

Tres De Febrero, Buenos Aires, Argentina, 1657

Bulgaria

Pleven, Bulgaria, 5800

Plovdiv, Bulgaria, 4002

Ruse, Bulgaria, 7002

Sofia, Bulgaria, 1606

Stara Zagora, Bulgaria, 6000

Canada, Alberta

Calgary, Alberta, Canada, T3B 6A8

Canada, Ontario

Hamilton, Ontario, Canada, L8N 3Z5

Canada, Quebec

Montreal, Quebec, Canada, H3H 1P3

Chile

Santiago, Chile

Czechia

Olomouc, Czechia, 77520

Prague, Czechia, 150 06

Germany

Stuttgart, Baden-Württemberg, Germany, 70176

Regensburg, Bayern, Germany, 93049

Wuppertal, Nordrhein-Westfalen, Germany, 42283

Greece

Athens, Greece, 115 27

Hungary

Budapest, Hungary, 1086

Gyor, Hungary, 9024

Latvia

Daugavpils, Latvia, LV-5417

Rezekne, Latvia, LV-4601

Riga, Latvia, LV1004

Lithuania

Kaunas, Lithuania, LT-50009

Vilnius, Lithuania, LT-08661

Mexico

México, D.F., Distrito Federal, Mexico, 04530

Ecatepec de Morelos, Estado De Mexico, Mexico, 55020

Guadalajara, Jalisco, Mexico, C.P. 44280

Peru

Cusco, Peru

Lima, Peru, LIMA 1

Lima, Peru

Romania

Iasi, Romania, 700309

Timisoara, Romania, 300011

Russian Federation

Smolensk, Russian Federation, 214019

Vladikavkaz, Russian Federation, 362019

Ukraine

Dnipropetrovsk, Ukraine, 49100

Ivano-Frankovsk, Ukraine, 76006

Lviv, Ukraine, 79004

Simferopol, Ukraine, 95034

Sponsors and Collaborators

Bayer

Investigators

• Study Director: Bayer Study Director; Bayer

More Information

Additional Information:

Click here to find information about studies related to Bayer Healthcare products conducted in Europe. 

Publications of Results:

Wirth S, Emil SGS, Engelis A, Digtyar V, Criollo M, DiCasoli C, Stass H, Willmann S, Nkulikiyinka R, Grossmann U; MOXIPEDIA Study Group. Moxifloxacin in Pediatric Patients With Complicated Intra-abdominal Infections: Results of the MOXIPEDIA Randomized Controlled Study. Pediatr Infect Dis J. 2018 Aug;37(8):e207-e213. doi: 10.1097/INF.0000000000001910.

• Responsible Party: Bayer
• ClinicalTrials.gov Identifier: NCT01069900
• Other Study ID Numbers: 11643; 1962 (Avelox pediatrics) ( Other Identifier: Company internal ); 2009-015578-37 ( EudraCT Number )
• First Posted: February 17, 2010
• Results First Posted: December 8, 2015
• Last Update Posted: March 20, 2018
• Last Verified: February 2018

Keywords provided by Bayer:

Intra-abdominal infection; Pediatric infection

Additional relevant MeSH terms:

Infections; Communicable Diseases; Intraabdominal Infections; Disease Attributes; Pathologic Processes; Amoxicillin; Moxifloxacin; Clavulanic Acid; Clavulanic Acids; Ertapenem; Amoxicillin-Potassium Clavulanate Combination; Norgestimate, ethinyl estradiol drug combination; Anti-Bacterial Agents; Anti-Infective Agents; Topoisomerase II Inhibitors; Topoisomerase Inhibitors; Enzyme Inhibitors; Molecular Mechanisms of Pharmacological Action; Antineoplastic Agents; Contraceptive Agents, Hormonal; Contraceptive Agents; Reproductive Control Agents; Physiological Effects of Drugs; Contraceptives, Oral, Combined; Contraceptives, Oral; Contraceptive Agents, Female; beta-Lactamase Inhibitors